Compare Quest Diagnostics Inc (DGX) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Marqeta Inc — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Marqeta Inc trades at $16.21 (market cap $1.70B). The key difference: Quest Diagnostics Inc is far larger — about 13.4× Marqeta Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| DGX | MQ | |
|---|---|---|
Market Cap | $22.80B | $1.70B |
Sector | Health | Technology |
52-Week High | $216.02 | $27.32 |
52-Week Low | $166.42 | $15.04 |
Enterprise Value | $28.82B | $999.94M |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Marqeta (MQ) trades at $16.43, up 3.53% with a bullish technical signal. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025, with revenue growth from $507M in 2024 to $625M in 2025. A recent 1-for-4 reverse stock split took effect on July 1, 2026. Cash flow improved to a net positive $86M in 2025. Analyst consensus is a $19 price target with 32% buy ratings.
Outlook is cautiously optimistic given earnings volatility and high valuation multiples. Opportunities include European expansion and credit product growth, but risks involve thin net margins and potential fiduciary duty lawsuits. The stock's upside depends on sustained profitability and execution of strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
